Wasting Syndrome (Cachexia) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Cachexia is a complex metabolic syndrome that arises from an underlying illness and is characterized by the loss of muscle mass, with or without the loss of fat mass. It often presents with anorexia, an inflammatory process, insulin resistance, and increased protein turnover. Cachexia leads to weight loss and an elevated risk of mortality. The primary cause of cachexia is an excess of cytokines. Additional contributing factors include deficiencies in testosterone and insulin-like growth factor-I, overabundance of myostatin, and excess glucocorticoids. Cachexia is distinguished by a persistent increase in the body's basal metabolic rate that is not compensated by an adequate intake of calories and protein. Various factors contribute to this abnormal metabolic cascade, including digestive issues, tumor-related factors, and hormonal responses to the underlying disease. Digestive factors that contribute to poor intake include dysgeusia (distorted sense of taste), nausea, dysphagia (difficulty swallowing), mucositis (inflammation of the mucous membranes), and constipation. Cachexia is categorized into pre-cachexia, cachexia, and refractory cachexia. The consensus definitions for these stages are as follows: Pre-cachexia: characterized by a weight loss of more than 1kg but less than 5% Cachexia: indicated by a weight loss of more than 5% or a weight loss of more than 2% with a body mass index (BMI) below 20kg/m^2 Refractory cachexia: defined by a weight loss of more than 15% with a BMI below 23kg/m^2 or a weight loss of more than 20% with a BMI below 27kg/m^2 Differential diagnoses for cachexia include the following conditions: Celiac disease, Crohn's disease, Cystic fibrosis, Dementia, Mercury poisoning, Motor neuron disease, Multiple sclerosis, Multiple systems, trophy, Parkinson's disease, and Rheumatoid arthritis.

  • The prevalence of cancer cachexia in the USA was reported to range between 11,300 (0.4 per 10,000, gastric cancer) and 92,000 patients (2.9 per 10,000, lung cancer).

Thelansis’s “Wasting Syndrome (Cachexia) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wasting Syndrome (Cachexia) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Wasting Syndrome (Cachexia) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Wasting Syndrome (Cachexia) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Wasting Syndrome (Cachexia) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more